An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Vabysmo

Chemical Namefaricimab-svoa
Dosage FormInjection (intravitreal; 120 mg/Ml)
Drug ClassInhibitors
SystemOcular
CompanyGenentech
Approval Year2022

Indication

  • For the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
  • For the treatment of patients with Diabetic Macular Edema (DME)
Last updated on 2/11/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vabysmo (faricimab-svoa) Prescribing Information. 2022Genentech, Inc., South San Francisco, CA
Document TitleYearSource
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.2022The Lancet
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trial. 2022The Lancet